<DOC>
	<DOCNO>NCT03085914</DOCNO>
	<brief_summary>This open-label , nonrandomized , Phase 1/2 study subject advance metastatic solid tumor . Phase 1 dose-escalation assessment evaluate safety tolerability epacadostat give combination PD-1 inhibitor chemotherapy . Once recommended dos determine , subject advance metastatic CRC , PDAC , NSCLC ( squamous nonsquamous ) , advance metastatic solid tumor progress previous therapy PD-1 PD-L1 inhibitor enrol Phase 2 .</brief_summary>
	<brief_title>A Study Epacadostat Combination With PD-1 Inhibitor Chemotherapy Subjects With Advanced Metastatic Solid Tumors ( ECHO-207 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Death</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis select advanced metastatic solid tumor . Presence measurable disease per RECIST v1.1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Laboratory medical history parameter within Protocoldefined range . Receipt anticancer medication investigational drug within Protocoldefined interval first administration study drug . Previous radiotherapy within 2 week start study therapy . Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has recover â‰¤ Grade 1 toxic effect previous therapy and/or complication previous surgical intervention start study therapy . Receipt live vaccine within 30 day plan start study therapy . Active infection require systemic therapy . Subjects active inactive autoimmune disease syndrome . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>pancreatic ductal adenocarcinoma</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>PD-1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>epacadostat</keyword>
	<keyword>IDO inhibitor</keyword>
</DOC>